Skip to content
Screener

Moderna MRNA Preferred Stock Par Value Per Share

Preferred Stock Par Value Per Share at other companies

ALN
Alnylam PharmaceuticalsALNY
$0.010.0%
Vaxcyte, Inc. logo
Vaxcyte, Inc.PCVX
$0.000.0%
Gilead Sciences logo
Gilead SciencesGILD
$0.000.0%

Other financials

Income statement

See full
Revenue$145.0M+2.1%
Gross profit$52.0M+126%
Operating income-$815.0M+10.1%
Net income-$782.0M+5.2%
EPS (diluted)-$1.97+7.5%

Balance sheet

See full
Cash & equivalents$1.7B+34.5%
Total debt$1.2B+60.8%
Total equity$6.8B-28.1%
Total assets$11.0B-8.7%

Cash flow

See full
Operating cash flow-$526.0M+42.8%
CapEx$37.0M+1,133%
Free cash flow-$563.0M+38.9%

Valuation

See full
Market cap$21.5B+107%
Enterprise value$21.01B+113%
P/S9.7×+6.3×

Profitability

See full
Gross margin23.4%-29.1pp
Operating margin-149%+99.9pp
Net margin-141.4%+141pp
FCF margin-132.4%

Returns & leverage

See full
Return on equity-39%+28.0pp
Debt / equity0.2×+0.1×
Current ratio2.3×-1.6×

Where this comes from

Reported directly by Moderna in its filing.

Tagged under the XBRL concept us-gaap:PreferredStockParOrStatedValuePerShare.

The source filing: Moderna’s 10-Q, filed May 1, 2026.

Filed
May 1, 2026, 4:10 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001682852-26-000060
Line itemMarch 31, 2026December 31, 2025
Total liabilities4,0803,688
Commitments and contingencies (Note 12)
Stockholders’ equity:
Preferred stock, par value $0.0001; 162 shares authorized as of March 31, 2026 and December 31, 2025; no shares issued or outstanding at March 31, 2026 and December 31, 2025
Common stock, par value $0.0001; 1,600 shares authorized as of March 31, 2026 and December 31, 2025; 397 and 394 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively
Additional paid-in capital1,5031,382
Accumulated other comprehensive income2545
Retained earnings5,8807,223

Item 1. Financial Statements (Unaudited)

FAQ

What is Moderna's preferred stock par value per share?
Moderna (MRNA) reported preferred stock par value per share of $0.00 in Q1 2026.
How has Moderna's preferred stock par value per share changed year-over-year?
Moderna's preferred stock par value per share decreased by 0.0% year-over-year, from $0.00 to $0.00.
What is the long-term trend for Moderna's preferred stock par value per share?
Over 5 years (2020 to 2025), Moderna's preferred stock par value per share has grown at a 0.0% compound annual growth rate (CAGR), from $0.00 to $0.00.
What does preferred stock par value per share mean?
The par value per share of preferred stock is a nominal value assigned to preferred shares for accounting and legal purposes. It does not reflect the market value or the liquidation preference of the stock. It is primarily a regulatory and historical accounting figure.

Ask your AI about Moderna's preferred stock par value per share.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude